FOXM1 and neoplasm: Palbociclib treatment significantly decreased tumour volume (Fig. 3a,b and Supplementary Fig. 10h), while increasing ROS (measured by 8-hydroxydeoxyguanosine34 and 4-hydroxynonenal35) and SA-ß gal activity, and lowering expression of bromo-2′-deoxyuridine (BrdU), pRb and FOXM1 in a dose-dependent manner (Fig. 3c,e and Supplementary Fig. 10i).